Client: Curis Pharma
Challenge:
Curis Pharma, a biopharmaceutical company focused on developing innovative therapeutics for cancer treatment, sought to effectively communicate the science behind their IRAK4/FLT3 inhibitor therapy in development for lymphoma and leukemia indications. Curis needed visually engaging and scientifically accurate exhibition booth panels for major international congresses, including the European Hematology Association (EHA), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH).
Solution:
PHASE II Scientific Communications provided Curis Pharma with full-service support for scientific exhibition booth panel development, encompassing every stage from initial concept to final production. Our approach included:
- Project Planning and Management: Dedicated project managers ensured timely completion of each panel development project, within budget and aligned with Curis Pharma’s communication objectives.
- Comprehensive Content Development:
- Thorough research to ensure scientific accuracy and currency.
- Compelling copywriting that effectively conveyed key messages to a diverse audience of healthcare professionals.
- Precise editing, referencing, and proofreading to maintain the highest quality standards.
- Original graphics, figures, and tables created using BioRender to visually represent complex scientific concepts.
- Visually Appealing Design: Incorporation of Curis Pharma’s branding guidelines to ensure a cohesive and recognizable presence at each congress.
- High-Resolution Artwork Preparation: Delivery of print-ready, high-resolution artwork for panel production.
- Logistics Management: Coordination with printing vendors and shipping companies to ensure timely delivery of panels to congress venues.
Key Activities:
- Panel development: Including research, copy writing, editing, referencing & proofing.
- Content development: Inclusive of origination of graphics, figures and tables using Biorender as well as developing all scientific / clinic copy, full proofing and provision of references.
- Preparation of final high-resolution artwork graphics for production/ printing of panels and shipping to the congress venue.
Results:
- Visually engaging and informative booth panels that effectively communicated the science behind Curis Pharma’s IRAK4/FLT3 inhibitor therapy.
- Enhanced Curis Pharma’s presence and visibility at major international congresses, facilitating interactions with key opinion leaders and potential partners.
- A streamlined panel development process, freeing up Curis Pharma’s internal resources to focus on other critical activities.
Conclusion:
This case study demonstrates PHASE II Scientific Communications’ ability to provide comprehensive and impactful scientific communication solutions for pharmaceutical and biotechnology companies. By combining scientific expertise, creative design, and project management excellence, PHASE II helps clients like Curis Pharma effectively communicate their science and achieve their strategic goals.
